ArticleJournal of clinical trials2016
Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma.
Article in Journal of clinical trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis.Cancer medicine · 2021Pooled it
- Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy.Frontiers in immunology · 2022Trial
- Global research trends and foci of ablation therapies for liver tumours: a scientometric study.Journal of gastrointestinal oncology · 2026Article
- Immunologic effects of locoregional therapies for unresectable hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2025Article
- Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review.BMC surgery · 2025Review
- Differential cytokine and chemokine expression after ablation vs. resection in colorectal cancer liver metastasis.Surgery open science · 2024Article
- Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation.Frontiers in immunology · 2023Article
- Synergizing liver systemic treatments with interventional oncology: friend or foe?The British journal of radiology · 2022Review
- Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy.Pharmaceutics · 2021Review
- Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review.The Journal of international medical research · 2021Review
- Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status.Journal of interventional medicine · 2021Review
- Hepatic thermal injury promotes colorectal cancer engraftment in C57/black 6 mice.American journal of physiology. Cell physiology · 2021Article
- Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy.Journal for immunotherapy of cancer · 2020Article
- Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment withWorld journal of gastroenterology · 2019Article
- Developing a Roadmap for Interventional Oncology.The oncologist · 2018Review
- Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer.Journal of immunology research and therapy · 2018Article
- Development of inCVAX,Journal of clinical & cellular immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Radiofrequency ablation (RFA) is an important treatment option for patients with early hepatocellular carcinoma (HCC). RFA offers a reliable, reproducible modality to effectively treat hepatic lesions with minimal collateral damage to the surrounding hepatic parenchyma. In addition to traditional open operative techniques, RFA can be performed percutaneously or laparoscopically to minimize the physiologic insult to the patient. Due to the concomitant hepatic damage and dysfunction that often is present in patients with HCC these factors make RFA a frequently utilized therapeutic option. However, RFA is most efficacious in treating smaller tumors (≤ 2 cm), particularly when an ablation margin of ≥ 4-5 mm can be obtained. RFA has diminishing utility in larger tumors, resulting in reduced three and five year overall survival rates when compared to surgical resection. Multimodal approaches to include RFA with other standard and investigational approaches have become a subject of recent interest. RFA capably produces cellular destruction causing liberation of a substantial amount of antigens, many of which are tumor-specific providing a favorable environment for immune recognition. We propose that utilizing an immunotherapeutic approach in conjunction with RFA is the next logical step in the treatment of HCC. In this review, we summarize how RFA modulates antitumor immunity and works in concert with immunotherapy in the treatment of HCC. The information provided is expected to help the future design of novel RFA-integrated immunotherapies which are able to generate durable and powerful antitumor immune response to achieve optimal tumor control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.